GRP78 has also been described as a receptor of angiogenic peptides and is known to interact with major histocompatibility complex class I. Cell-surface GRP78 expression has been detected in many different cancers, such as breast, liver, prostate, and pancreatic tumour tissue, and has been associated with the development of drug resistance and cell transformation [40, 41]. Here, HSPA5 is linked to cancer.